Novel Biomarkers of Diabetic Kidney Disease

Diabetic kidney disease (DKD) is a highly prevalent condition worldwide. It represents one of the most common complications arising from diabetes mellitus (DM) and is the leading cause of end-stage kidney disease (ESKD). Its development involves three fundamental components: the hemodynamic, metabolic, and inflammatory axes. Clinically, persistent albuminuria in association with a progressive decline in glomerular filtration rate (GFR) defines this disease. However, as these alterations are not specific to DKD, there is a need to discuss novel biomarkers arising from its pathogenesis which may aid in the diagnosis, follow-up, therapeutic response, and prognosis of the disease.

[1]  K. Khunti,et al.  KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. , 2022, Kidney international.

[2]  Ketan Mangukiya,et al.  Early detection of acute renal failure by serum cystatin C in type 2 diabetes patients in Parul Sevashram hospital at Waghodia, Vadodara , 2022, Medical Science.

[3]  G. Aroca,et al.  Molecular Mechanisms of Diabetic Kidney Disease , 2022, International journal of molecular sciences.

[4]  B. Isermann,et al.  Neutrophil Extracellular Traps Promote NLRP3 Inflammasome Activation and Glomerular Endothelial Dysfunction in Diabetic Kidney Disease , 2022, Nutrients.

[5]  R. Jorge,et al.  Inflammation and Diabetic Kidney Disease: New Perspectives , 2022, Journal of Biomedical Research & Environmental Sciences.

[6]  K. Gist,et al.  Improving acute kidney injury diagnostic precision using biomarkers , 2022, Practical laboratory medicine.

[7]  M. Monteiro,et al.  Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease , 2022, Medicinal research reviews.

[8]  T. Yoo,et al.  Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease , 2022, Diabetes & metabolism journal.

[9]  K. Jeong,et al.  Acute Kidney Injury: Biomarker-Guided Diagnosis and Management , 2022, Medicina.

[10]  Sopida Thipsawat.  Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature , 2021, Diabetes & vascular disease research.

[11]  R. Vasan,et al.  Associations of Plasma Biomarkers of Inflammation, Fibrosis, and Kidney Tubular Injury With Progression of Diabetic Kidney Disease: A Cohort Study. , 2021, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  Jorge Rico-Fontalvo,et al.  Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review , 2021, Kidney medicine.

[13]  K. Mahaffey,et al.  Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial , 2021, Diabetologia.

[14]  Nehomar Pájaro Galvis,et al.  Proteoma urinario en la enfermedad renal diabética. Estado del arte: Urinary proteome in diabetic kidney disease: state of the art , 2021 .

[15]  N. Samsu.  Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment , 2021, BioMed research international.

[16]  H. Heerspink,et al.  Precision medicine approaches for diabetic kidney disease: opportunities and challenges , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  E. Ferrannini,et al.  Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes , 2021, The Journal of clinical endocrinology and metabolism.

[18]  R. DeFronzo,et al.  Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors , 2021, Nature Reviews Nephrology.

[19]  G. Gruden,et al.  Novel biomarkers of diabetic kidney disease: current status and potential clinical application , 2021, Acta Diabetologica.

[20]  R. Vasan,et al.  Association of Multiple Plasma Biomarker Concentrations with Progression of Prevalent Diabetic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. , 2020, Journal of the American Society of Nephrology : JASN.

[21]  L. Forni,et al.  Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement. , 2020, JAMA network open.

[22]  Correa-Basurto José,et al.  SGLT2 Inhibitors and nephroprotection in diabetic kidney disease: From mechanisms of action to the latest evidence in the literature , 2020 .

[23]  D. de Zeeuw.  The future of Diabetic Kidney Disease management: reducing the unmet need , 2020, Journal of Nephrology.

[24]  Chen Huang,et al.  Significance of Neutrophil Gelatinase-Associated Lipocalin as a Biomarker for the Diagnosis of Diabetic Kidney Disease: A Systematic Review and Meta-Analysis , 2020, Kidney and Blood Pressure Research.

[25]  G. Nijpels,et al.  Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. , 2020, The lancet. Diabetes & endocrinology.

[26]  A. Esteghamati,et al.  Neutrophil Gelatinase-Associated Lipocalin and Retinol-Binding Protein-4 as Biomarkers for Diabetic Kidney Disease , 2020, Kidney and Blood Pressure Research.

[27]  A. Heinzel,et al.  Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease , 2019, Diabetologia.

[28]  M. von Eynatten,et al.  Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase‐4 Inhibition: A Hypothesis‐Generating Analysis from the MARLINA‐T2D Trial , 2019, Proteomics. Clinical applications.

[29]  M. Marcovecchio,et al.  Biomarkers of diabetic kidney disease , 2018, Diabetologia.

[30]  R. Nelson,et al.  Role of Kidney Biopsies for Biomarker Discovery in Diabetic Kidney Disease. , 2018, Advances in chronic kidney disease.

[31]  B. Satirapoj.  Tubulointerstitial Biomarkers for Diabetic Nephropathy , 2018, Journal of diabetes research.

[32]  N. Prasad,et al.  Neutrophil Gelatinase-associated Lipocalin: As a Predictor of Early Diabetic Nephropathy in Type 2 Diabetes Mellitus , 2018, Indian journal of nephrology.

[33]  S. Hadjadj,et al.  Plasma concentrations of 8-hydroxy-2′-deoxyguanosine and risk of kidney disease and death in individuals with type 1 diabetes , 2018, Diabetologia.

[34]  G. Laverman,et al.  The albuminuria‐lowering response to dapagliflozin is variable and reproducible among individual patients , 2017, Diabetes, obesity and metabolism.

[35]  L. Fried,et al.  Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease. , 2017, Journal of the American Society of Nephrology : JASN.

[36]  K. Budde,et al.  Biomarkers in acute kidney injury – pathophysiological basis and clinical performance , 2017, Acta physiologica.

[37]  H. Parving,et al.  Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[38]  H. Mischak,et al.  Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease , 2016, Diabetologia.

[39]  J. Delanghe,et al.  Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes. , 2016, Clinical biochemistry.

[40]  J. Skupień,et al.  Increased plasma Kidney Injury Molecule-1 suggests early progressive renal decline in non-proteinuric patients with Type 1 diabetes , 2015, Kidney international.

[41]  F. Agakov,et al.  Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. , 2015, Kidney international.

[42]  S. Adler,et al.  Prevalence and Management of Diabetic Nephropathy in Western Countries , 2015, Kidney Diseases.

[43]  R. Bellomo,et al.  Assessment of Cell-Cycle Arrest Biomarkers to Predict Early and Delayed Acute Kidney Injury , 2015, Disease markers.

[44]  Yuekang Xu,et al.  Cystatin C is a disease‐associated protein subject to multiple regulation , 2015, Immunology and cell biology.

[45]  H. Parving,et al.  Improved prognosis of diabetic nephropathy in type 1 diabetes. , 2015, Kidney international.

[46]  W. Knowler,et al.  Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes , 2014, Kidney international.

[47]  J. Navarro-González,et al.  Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. , 2015, Journal of the American Society of Nephrology : JASN.

[48]  P. D. De Jager,et al.  Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. , 2014, Journal of the American Society of Nephrology : JASN.

[49]  S. Adler,et al.  Comprehensive approach to diabetic nephropathy , 2014, Kidney research and clinical practice.

[50]  A. Galecki,et al.  Synergism Between Circulating Tumor Necrosis Factor Receptor 2 and HbA1c in Determining Renal Decline During 5–18 Years of Follow-up in Patients With Type 1 Diabetes and Proteinuria , 2014, Diabetes Care.

[51]  Merlin C. Thomas,et al.  Added Value of Soluble Tumor Necrosis Factor-α Receptor 1 as a Biomarker of ESRD Risk in Patients With Type 1 Diabetes , 2014, Diabetes Care.

[52]  J. Skupień,et al.  Early Progressive Renal Decline Precedes the Onset of Microalbuminuria and Its Progression to Macroalbuminuria , 2013, Diabetes Care.

[53]  Lawrence A Leiter,et al.  Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial , 2013, The Lancet.

[54]  K. Hunt,et al.  Baseline Markers of Inflammation Are Associated With Progression to Macroalbuminuria in Type 1 Diabetic Subjects , 2013, Diabetes Care.

[55]  C. Forsblom,et al.  Urinary Liver-Type Fatty Acid–Binding Protein and Progression of Diabetic Nephropathy in Type 1 Diabetes , 2013, Diabetes Care.

[56]  Y. Jeon,et al.  Urinary Cystatin C and Tubular Proteinuria Predict Progression of Diabetic Nephropathy , 2013, Diabetes Care.

[57]  Woo-In Lee,et al.  Cystatin C as an early marker of diabetic nephropathy in patients with type 2 diabetes. , 2013, Clinical laboratory.

[58]  M. Serdar,et al.  Comparison of 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels using mass spectrometer and urine albumin creatinine ratio as a predictor of development of diabetic nephropathy , 2012, Free radical research.

[59]  S. Adler,et al.  Novel insights into the relationship between glomerular pathology and progressive kidney disease. , 2012, Advances in chronic kidney disease.

[60]  T. Mayadas,et al.  Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[61]  A. Elmarakby,et al.  Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. , 2012, Cardiovascular therapeutics.

[62]  Olga Vasiljeva,et al.  Cysteine cathepsins: From structure, function and regulation to new frontiers , 2011, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics.

[63]  S. Bakker,et al.  Glomerular and Tubular Damage Markers Are Elevated in Patients With Diabetes , 2011, Diabetes Care.

[64]  Rinaldo Bellomo,et al.  Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery—A prospective cohort study* , 2009, Critical care medicine.

[65]  J Concato,et al.  Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. , 2008, Kidney international.

[66]  L. Jianping,et al.  Urinary IL-18 and NGAL as Early Predictive Biomarkers in Contrast-Induced Nephropathy after Coronary Angiography , 2008, Nephron Clinical Practice.

[67]  Guowang Xu,et al.  Study of urinary 8-hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in diabetic nephropathy patients. , 2004, Journal of pharmaceutical and biomedical analysis.

[68]  A. Kribben,et al.  Early detection of acute renal failure by serum cystatin C. , 2004, Kidney international.

[69]  P. Chang,et al.  Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[70]  H. Siragy,et al.  Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. , 2003, Kidney international.

[71]  V. Dharnidharka,et al.  Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[72]  P. Libby,et al.  Cystatin C deficiency in human atherosclerosis and aortic aneurysms. , 1999, The Journal of clinical investigation.

[73]  M. Kondo,et al.  Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. , 1991, Kidney international.

[74]  N. Perico,et al.  Tumor necrosis factor induces glomerular damage in the rabbit. , 1989, The American journal of pathology.